Background
==========

Medullary thyroid carcinoma (MTC) arises from the parafollicular C cells of the thyroid gland, which secrete calcitonin ([@bib1]). MTC is a rare neuroendocrine tumor that accounts for only 3--5% of all thyroid carcinomas, being responsible for up to 13.4% of all thyroid  cancer-related deaths ([@bib2]). The 10-year survival rate of patients with MTC is influenced by the stage of the disease at presentation, reaching up to 96% when the tumor is confined to the thyroid gland, and decreasing to about 26% when distant metastases are present, previously to the introduction of tyrosine kinases inhibitors therapy ([@bib3]).

MTC produces calcitonin, which is a specific serum marker; it may also secrete carcinoembryonic antigen (CEA) and other peptides such as adrenocorticotropic hormone (ACTH), corticotrophin-releasing hormone (CRH), serotonin, vasoactive intestinal peptide and others ([@bib4]). Ectopic Cushing syndrome due to ectopic ACTH secretion (EAS) by MTC is an uncommon and poor prognostic event, being associated with significant morbidity and mortality, as the associated complications of hypercortisolism cause death in about 50% of these patients ([@bib5]). Medical therapy with inhibitors of steroidogenesis or ACTH secretion to control the complications of hypercortisolism is often unsuccessful, and bilateral adrenalectomy may be required.

Vandetanib (Caprelsa, ZD6474; AstraZeneca), a tyrosine kinase inhibitor selectively targeting the RET receptor, the epidermal growth factor receptor (EGFR) and the vascular endothelium growth factor receptor (VEGFR), is approved for the treatment of symptomatic, progressive MTC in patients with locally advanced, unresectable or metastatic disease. Several case reports have recently described the reversal of Cushing's syndrome-related symptoms induced by the known anti-secretory effect of vandetanib; however, to date, no tumor size reduction has been reported in Ectopic MTC-related Cushing's patients treated with vandetanib ([@bib6]).

In this manuscript, we present a patient with sporadic long-standing metastatic MTC that developed EAS after 20 years of disease, in parallel with tumor progression. After the failure of treatment with metyrapone, vandetanib was initiated, inducing a significant clinical improvement, in parallel with both biochemical response and tumor regression.

Case presentation
=================

A 55-year-old woman was diagnosed with sporadic MTC and underwent total thyroidectomy 20 years ago. After the first surgery, elevated calcitonin levels in parallel with local and neck lymph node disease persistence were noted and therefore she underwent repeated modified neck dissections; despite the relative decrease in serum calcitonin levels after the procedures, they never completely normalized. During follow-up, multiple foci of metastatic disease were noted in the neck and mediastinal lymph nodes, as well as in the lungs and the bones; however, the disease had an indolent course with a very slow progression rate for a number of years, both clinically (no significant symptoms) and on whole-body high-resolution CT scan imaging, in parallel with a calcitonin doubling time of more than two years. However, about three years ago, she started to suffer from secretory diarrhea and flushing, and treatment with monthly injections of somatostatin analogue Somatuline Depot 120 mg (lanreotide Autogel) (Ipsen Pharma) was initiated, after a somatostatin receptor imaging with  Ga^68^-DOTATATE-PET-CT showing an increased uptake in some of the tumor-related metastases. Although the diarrhea and the flushing partially improved, the treatment was interrupted due to the development of acute colitis and bowel perforation, requiring surgical intervention. During a routine follow-up visit two years ago, findings suggestive of Cushing's syndrome, namely moon face and plethora, central obesity, peripheral edema, hirsutism, acne and buffalo hump together with hypertension were observed on physical examination.

Investigation
=============

The biochemical evaluation at that time ([Table 1](#tbl1){ref-type="table"}) demonstrated marked elevations of serum calcitonin levels up to 111 760 pg/mL, compared with 67 377 pg/mL  six months earlier (normal \<5 pg/mL), CEA 494 ng/mL (previous 209 ng/mL, normal \<4.6 ng/mL), in parallel with lack of cortisol suppression after an overnight 1 mg dexamethasone suppression test, lack of cortisol and ACTH suppression after high-dose IV dexamethasone 8 mg test, elevated plasma ACTH up to 79 pg/mL (normal \<46 pg/mL) and elevated 24 h urinary free cortisol up to 501 µg/24 h (normal 9--90 µg/24 h). After a normal pituitary MRI, she underwent an inferior petrosal sinus sampling, which was compatible with EAS ([Table 2](#tbl2){ref-type="table"}). Whole-body CT demonstrated progressive disease at most of the tumor sites. Table 1The biochemical evaluation at ectopic Cushing's syndrome diagnosis.**ParametersNormal valuesAt EAS diagnosis6 months earlier**Calcitonin, pg/mL\<5111 76067   377CEA, ng/mL\<4.6494209Cortisol (nmol/mL) after DST 1 mg\<50634 DST 8 mg\<50540ACTH, pg/mL\<4679UFC, μg/24 h9--90501 Table 2Inferior petrosal sinus sampling results compatible with ectopic Cushing's syndrome. If the pituitary-to-peripheral ratio (PPR) is less than 1.5 (less than 3 if CRH was given), the patient has ectopic Cushing's.**Time** (min)\***RightLeftPeripheryPPRPeriphery**−549.4\*\*51.70.95911061.6--55.11.11878333.7--510.66914561.7--43.41.429741053.5--44.91.1998020--51924[^1][^2]

Treatment
=========

Based on a low body mass index (BMI), treatment with vandetanib at a reduced dosage of 200 mg/day was commenced. However, the dosage was further decreased to 100/200 mg/day, alternate days, due to the prolongation of the QT interval on electrocardiography.

Outcome and follow-up
=====================

The patient showed a significant and rapid clinical improvement (the blood pressure normalized, the edema, plethora and acne completely disappeared and the fatigue improved) already two months after treatment initiation, in parallel with biochemical improvement ([Table 3](#tbl3){ref-type="table"}). The clinical and biochemical improvement has continued until the time of this publication (9 months since treatment start), whereas a decrease in tumor size was also demonstrated on follow-up CT ([Fig. 1](#fig1){ref-type="fig"}). Figure 1Computed tomography of the neck and chest showing a decrease in tumor size observed in our patient under the treatment with vandetanib. Axial CT images with contrast of the chest: Heterogeneous masses are seen in the upper mediastinum (arrows) before the treatment (A); there is decrease in their size after treatment (B). Heterogeneous masses are seen in the mediastinal (arrow) and hilum areas (curved arrow), demonstrating microcalcifications (C); after treatment, the masses have decreased in size. (D) Coronal CT images with contrast of the chest: The metastatic disease is seen in the upper mediastinum (asterisk) and lung hilum bilaterally (arrows) (E); decrease in lesions size after treatment (F). Table 3The biochemical evaluation before and during treatment with vandetanib.**Biochemical evaluation**Normal values**Before treatment with vandetanibAfter 2 months of vandetanib treatment**Calcitonin (pg/mL)\<5111 76013 132ACTH (pg/mL)\<467931UFC (µg/24 h)9--9050128

Discussion
==========

ACTH-dependent ectopic Cushing's syndrome is responsible for approximately 15% of adult Cushing's syndrome. Cushing's syndrome due to ectopic ACTH secretion (EAS) by MTC is rare and associated with poor prognosis, as up to 80% of these patients do not survive more than \~12.8 months after the diagnosis of hypercortisolemia ([@bib7]). The diagnosis of MTC-related Cushing's syndrome is based on the presence of hypercortisolism (with high or inappropriately normal ACTH concentrations) that is not suppressed by high-dose dexamethasone, the absence of a pituitary adenoma and the  parallel progression of Cushing's syndrome and MTC ([@bib4], [@bib8]).

The usual treatment of these patients involves either chemical (using adrenolytic drugs such as ketoconazole, metyrapone, etomidate, etc.) or surgical adrenalectomy, in an attempt to control the severe hypercortisolism and its related morbidity ([@bib5]).

Vandetanib, a tyrosine kinase inhibitor targeting a variety of receptors involved in tumor progression (e.g., the RET receptor, the epidermal growth factor receptor (EGFR), the vascular endothelial growth factor receptor-2 (VEGFR)), has been proven effective in patients with progressive MTC, both sporadic and familial types ([@bib9]). Since its approval in 2011 by the Food and Drug Administration in the United States, a few case reports demonstrated that vandetanib may be effective for control of EAS-related symptoms in patients with advanced MTC ([@bib8], [@bib9]). Two recent reports suggested that vandetanib effectively reversed the ACTH-dependent ectopic Cushing's syndrome in two adult patients with MTC, and this effect was confirmed in a young adolescent patient with MTC-related Cushing's syndrome also; interestingly, the control of the hypercortisolism was prolonged and independent of MTC tumor progression ([@bib5], [@bib6], [@bib8]). However, no clear anti-proliferative tumor effect was reported to date, in terms of reduction in tumor size, in patients with MTC-related EAS ([Table 4](#tbl4){ref-type="table"}). Table 4A summary of the case reports of ectopic Cushing's syndrome related to medullary thyroid carcinoma, including our patient, who received vandetanib, to date (adapted from Pitoia F *et al*. Arch Endocrinol Metab. 2015;59(4):343--6).**Case reportMTC type (familial/sporadic)Treatment dose of vandetanibTreatment duration** (months)**Response of EAS** (days)**Tumor responseTreatment withdrawal/under treatment**Nella *et al.* ([@bib8])MEN 2B200 mg/day2930StableTumor progressionBaudry *et al*. ([@bib6])Not reported300 mg/day4.215StableNot reportedFabián *et al*. ([@bib10])Not reported300 mg/day830StableUnder treatmentThis reportSporadic100/200 mg/day, alternately10, continuing30Partial responseUnder treatment

In the present report, the rapid control of the hypercortisolism with vandetanib treatment is in agreement with the hypothesis that this class of drugs could have a cortisol-lowering effect by blocking CRH and/or ACTH secretion by the tumor cells ([@bib6]). In addition, the decrease in tumor size observed in our patient suggests that vandetanib treatment may also have an antiproliferative effect in the rare patients with MTC-associated EAS.

Our report confirms the previous findings by showing that treatment with vandetanib may effectively control the signs and symptoms related to ectopic ACTH secretion in patients with advanced progressive MTC and that it is also effective in decreasing tumor size and inducing tumor control. Additional studies are needed to assess the anti-secretory effect in other neuroendocrine tumor-related EAS and to confirm our observation on vandetanib anti-tumor effect.

Patient's perspective
=====================

We welcome comments from your patient; their own description of their experience may help other patients or clinicians who are dealing with a similar problem. If your patient would like to contribute please ensure they include only relevant personal details. Patients may describe their symptoms, how any tests and treatments affected them and how the problem is now.
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[^1]: related to CHR injection

[^2]: Not performed due to technical difficulties.
